Eden vs GALA vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping Eden, GALA GLP-1, and PlexusDx for cash-pay GLP-1 weight loss, the headline numbers don’t tell the whole story. Eden advertises $129 first month / $249/mo after on its 3-month compounded semaglutide plan. GALA advertises $179/mo on its annual GLP-1/GIP plan and $149/mo for microdosing. PlexusDx advertises Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, and GLP-Squared at $249/mo. This article walks the actual cost math, the cancellation and refund rules, the medication breadth, and where the Precision Peptide Genetic Test changes the conversation — because the real choice is about menu breadth, refund protection, total annualized cost, and whether genetics inform your dose before week one.

Eden vs GALA vs PlexusDx — quick decision frame

Three pricing models cover the cash-pay compounded GLP-1 market. Eden is the broad-menu telehealth platform: $129 first month / $249/mo after on the 3-month compounded semaglutide plan, $249 first month / $329/mo after on compounded tirzepatide, plus brand-name Wegovy, Ozempic, Zepbound, and Mounjaro at higher cash-pay rates. GALA GLP-1 is the lowest-headline-price commitment play: $179/mo on the annual GLP-1/GIP plan (which bundles tirzepatide), $199/mo on the 3-month plan, and $149/mo for microdosing on the annual plan — plus integrated hormone replacement therapy on the same platform. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Semaglutide Oral from $249/mo, Tirzepatide Oral at $279/mo, and GLP-Squared at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing decisions are anchored to the patient’s GLP1R, FTO, MC4R, and TCF7L2 variants rather than starting from population averages. All three are cash-pay; none has a membership fee.

The real annual cost: Eden vs GALA vs PlexusDx

For a cash-pay patient with no insurance coverage for weight-loss drugs, year-one totals tell the real story. Eden’s 3-month compounded semaglutide plan runs roughly $2,428/year ($129 first month + $209 × 11). Eden’s monthly compounded tirzepatide plan runs roughly $3,868/year ($249 first month + $329 × 11). GALA’s annual GLP-1/GIP plan runs $2,148/year ($179 × 12) and the microdosing annual plan runs $1,788/year ($149 × 12). PlexusDx Weight Management Protocols range from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), and $2,148–$3,900/year on GLP-Squared ($249/mo). Add $99 once for the Precision Peptide Genetic Test as a post-month-one add-on, and PlexusDx totals stay below Eden on the lower tiers and competitive with GALA’s annual commitment without a 12-month contract. PlexusDx Microdose GLP-1 Protocol at $1,548/year is the lowest verified annual cost here.

Medication menu — what each provider actually carries

This is where the three providers diverge most. Eden carries the broadest menu among telehealth-only platforms in this comparison: compounded semaglutide and tirzepatide, brand-name Wegovy, Ozempic, Zepbound, and Mounjaro, plus oral semaglutide, GLP-1 Rx gummies, and Custom Weight Loss Kits. GALA carries a focused compounded GLP-1/GIP product (semaglutide + tirzepatide blend), microdosing GLP-1/GIP as a labeled product, brand-name Ozempic at higher cash-pay rates, and integrated HRT (estradiol pill or patch, progesterone, vaginal estradiol, non-hormonal options). Wegovy pill is listed as “coming soon” on GALA. PlexusDx Weight Management Protocols cover six compounded products across four mechanism classes — Microdose GLP-1 Protocol, Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, Tirzepatide Oral, and GLP-Squared (Semaglutide + Tirzepatide stacked). PlexusDx does not dispense brand-name Wegovy, Zepbound, or Mounjaro — if a brand-name FDA-approved finished drug is non-negotiable, Eden is the only provider in this comparison that routes those directly.

Compounded vs FDA-approved — the regulatory reality

Compounded semaglutide and tirzepatide are not FDA-approved finished drug products. They are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound, prepared by state-licensed 503A compounding pharmacies under U.S. compounding regulations. The FDA does not review compounded products for safety, efficacy, or quality before marketing. As of July 31, 2025, the FDA had received approximately 1,150 adverse-event reports related to compounded versions of semaglutide and tirzepatide. Eden, GALA, and PlexusDx all dispense compounded GLP-1 products through licensed pharmacies; none should be described as offering “FDA-approved” semaglutide or tirzepatide. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — that warning travels with the active ingredient. Eden additionally routes brand-name Wegovy, Zepbound, Mounjaro, and Ozempic, which are FDA-approved finished products carrying the FDA label and post-market surveillance directly.

Cancellation, refunds, and the 72-hour rule

This is the part most comparison pages skip and it materially changes the cost-of-mistake calculation. Eden allows cancellation through the patient portal at any time, with the caveat that if your prescription has already been sent to the pharmacy, portal cancellation will not stop that order — you would need to contact Eden support directly. Eden’s published refund policy allows prorated refunds when its pharmacy network cannot fulfill due to drug shortages, FDA regulations, or other external factors. GALA requires you to submit a cancellation request at least 72 hours before your billing date to avoid being charged for the next cycle — a deadline that catches first-time GLP-1 patients off guard, especially on the annual plan. GALA refunds the full amount only if you’re medically disqualified during evaluation; otherwise no refund is issued upon cancellation. PlexusDx is cash-pay with no membership and no annual commitment. PlexusDx Weight Management Protocols are billed monthly at the current dose tier; PlexusDx is in all 50 states (five require a scheduled live consultation rather than async intake). For a first-time patient uncertain about tolerability, Eden’s portal cancellation plus PlexusDx’s no-commitment monthly billing both reduce the cost of changing your mind more than GALA’s 72-hour-deadline annual plan.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), FTO (appetite regulation), MC4R (satiety signaling), TCF7L2 (insulin response), and GIPR rs1800437 (the headline GIP-receptor variant linked to differential GLP-1 response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways — including 34 weight-management insights — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither Eden nor GALA performs this step — both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone at $298 or as a $99 add-on after your first month on any protocol. Those “why doesn’t GLP-1 work for me” and “should I be on tirzepatide instead of semaglutide” questions are exactly what a genetic baseline informs.

Which one fits — a four-question frame

Question 1: Do you want a brand-name FDA-approved finished GLP-1 (Wegovy, Zepbound, Mounjaro)? Eden is the only provider in this comparison that routes those directly. Question 2: Is the lowest committed price for compounded tirzepatide-style care your dominant criterion and you are confident you will stay on treatment for 12 months? GALA’s $179/mo annual GLP-1/GIP plan is the lowest verified compounded tirzepatide-bundled price in this comparison. Question 3: Are you cash-pay with no insurance coverage and you want the lowest entry price without an annual commitment? Compare Eden’s $129 first month / $249/mo after to PlexusDx Microdose GLP-1 Protocol at $129/mo flat — PlexusDx’s flat pricing eliminates the post-promo price jump. Question 4: Do you want a genetic baseline informing dose and titration before the first injection, plus dose flexibility across injection, oral, microdose, and dual-compound formats? PlexusDx is the only option here that includes the Precision Peptide Genetic Test as part of the protocol pathway, with six compounded products spanning four mechanism classes.

Frequently asked questions

Is Eden GLP-1 cheaper than GALA?

For compounded semaglutide, Eden’s 3-month plan ($129 first month, $249/mo after) is roughly $50 cheaper than GALA’s $199/mo 3-month plan over the first 3 months. For compounded tirzepatide-style care, GALA is meaningfully cheaper — GALA’s annual plan is $179/mo while Eden’s compounded tirzepatide is $329/mo on the monthly plan, a difference of roughly $1,720 over a year. PlexusDx Microdose GLP-1 Protocol at $129/mo flat ($1,548/year) is the lowest annual cost in this comparison and does not require an annual commitment.

Does Eden carry tirzepatide and does GALA carry tirzepatide?

Yes to both, but differently. Eden offers compounded tirzepatide as a standalone product at $249 first month / $329/mo after on the monthly plan, plus brand-name Mounjaro and Zepbound. GALA bundles tirzepatide into a compounded GLP-1/GIP product at $179/mo on the annual plan, $199/mo on the 3-month plan, and $149/mo for the microdosing variant. PlexusDx offers Tirzepatide Injection at $249/mo across six dose levels and Tirzepatide Oral at $279/mo across seven dose levels.

Does Eden or GALA accept insurance?

No. Both are cash-pay only. Eden accepts HSA/FSA cards for most visits and prescriptions. GALA’s HSA/FSA acceptance is not stated on its homepage — verify at checkout if HSA/FSA matters to you. PlexusDx is also cash-pay only with no membership; insurance is not accepted on any of the six PlexusDx Weight Management Protocols.

Are compounded GLP-1 medications FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved. Only branded finished products like Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Trulicity, and Victoza are FDA-approved. As of July 31, 2025, the FDA had received approximately 1,150 adverse-event reports related to compounded versions of semaglutide and tirzepatide. Eden, GALA, and PlexusDx all dispense compounded products through licensed pharmacies and do not market them as FDA-approved.

Can I cancel Eden, GALA, or PlexusDx anytime?

Eden allows cancellation through the patient portal at any time, with prorated refunds if its pharmacy network cannot fulfill due to shortages or FDA action. GALA requires cancellation at least 72 hours before your billing date and refunds only if you are medically disqualified during evaluation. PlexusDx Weight Management Protocols are billed monthly with no annual commitment; you can stop your subscription between monthly cycles.

Which is better for first-time GLP-1 users?

Eden is friendlier than GALA for first-time users because of the lower first-month entry ($129 on the 3-month sema plan), portal-based cancellation without a 72-hour deadline, and the prorated refund clause if a pharmacy cannot fulfill. PlexusDx is also a strong first-time fit: Microdose GLP-1 Protocol at $129/mo flat removes the post-promo price jump, no annual commitment, and the optional Precision Peptide Genetic Test at $99 as an add-on means your first dose decision is anchored to your biology rather than a population-average schedule.

How does PlexusDx compare to Eden and GALA on dose flexibility?

PlexusDx covers six compounded products across four mechanism classes — Microdose GLP-1 Protocol, Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, Tirzepatide Oral, and GLP-Squared. That is the broadest compounded GLP-1 menu in this comparison and the only one that pairs every protocol with an optional genetic baseline. Eden has the broader brand-name FDA-approved menu; GALA is the narrowest of the three on compounded breadth but adds integrated HRT.

Eden vs GALA GLP-1 vs PlexusDx (2026): Pricing, Plans and Who Should Pick Which | PlexusDx